QCM
ARQT icon

Quantinno Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Quantinno Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$574K Buy
21,898
+2,785
+15% +$64.9K ﹤0.01% 2909
2026
Q1 		$450K Buy
19,113
+257
+1% +$6.56K ﹤0.01% 2789
2025
Q4 		$548K Buy
+18,856
New +$483K ﹤0.01% 2343

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Quantinno Capital Management's ARQT Position: Q2 2026 in Review

Quantinno Capital Management increased its Arcutis Biotherapeutics (ARQT) stake by 15% in Q2 2026, buying an estimated $64.9K and bringing the position to 21,898 shares worth $574K. The position accounts for ﹤0.01% of the portfolio, ranked #2909.

Quantinno Capital Management first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Quantinno Capital Management held 21,898 shares of Arcutis Biotherapeutics worth $574K as of Q2 2026.
  • Quantinno Capital Management bought 2,785 Arcutis Biotherapeutics shares in Q2 2026, an estimated $64.9K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2909 holding.
  • Quantinno Capital Management first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.